Disclosures

1. What Klarovel is (and is not)

Klarovel is a global peptide intelligence platform. We publish research-grade educational content on peptides, protocols, and longevity science, and we connect users to a vetted network of third-party distributors for the supply of high-quality peptides for research purposes only.

Klarovel is not a pharmacy, not a clinic, not a medical practice, and not a healthcare provider. We do not manufacture, hold, or ship peptides ourselves. Every fulfilment relationship is documented in our partner-supplier model: the user places an order through Klarovel, our admin team confirms availability with the relevant distributor, the distributor ships the product, and the financial and physical custody chain runs between the user and that distributor. Klarovel sits beside the transaction as the protocol layer, not inside it as the supplier.

The protocol itself is generated by a deterministic rules engine, not by a chatbot and not by a clinician. The engine evaluates the user's submitted health questionnaire, optional bloodwork, and goal profile against a curated peptide catalogue; it surfaces recommended peptides, doses, cycling, stacking, and monitoring rules; and it logs every decision so the output is reproducible. The same inputs produce the same protocol every time.

2. Who this content is for

Our content is written for an informed, technically literate audience: researchers, clinicians, biohackers, longevity-curious readers, and others who want to understand peptide science at primary-source depth. We assume the reader is capable of judging the relevance and limits of preclinical and clinical data.

We do not write for first-time peptide-curious readers who want a quick answer to "should I take this?" That question is for a qualified clinician with access to the reader's full medical history. Our content is upstream of that conversation: it gives readers the vocabulary, the citation trail, and the mechanistic framing to ask the right questions when they get to a clinician. Treating peptide science as a consumer purchase decision rather than a clinical evaluation is the failure mode we are explicitly built to avoid.

3. Editorial and medical review

Every long-form post is reviewed before publication by the Klarovel Medical Advisory Board, an independent editorial review function inside Klarovel that checks each piece for: claim sourcing against peer-reviewed literature; dose statements against the published peptide research catalogue; regulatory accuracy where the post touches jurisdiction-specific rules; and tone consistent with our wellness-information posture.

Each post carries the date of its most recent review. When regulatory facts, study results, or pricing change materially, the affected post is reviewed again and the review date updated. Pure cosmetic edits (a typo fix, an SEO meta-tag tweak, a non-load-bearing rephrasing) do not bump the review date because the review date is a clinical-vouching signal, not a last-touched timestamp. This distinction matters because Google reads the date as a recency-of-clinical-review marker for medical content, and inflating it would dilute the signal.

4. Sources and citation standards

Every load-bearing factual claim in a Klarovel post carries an inline hyperlink to a primary source. The hierarchy we use, in descending order of weight: peer-reviewed primary literature (PubMed, indexed journals); regulator publications (FDA, EMA, Statens legemiddelverk, MHRA, TGA); recognised guideline bodies (Helsedirektoratet, FHI, NICE, USPSTF, WHO); vendor-neutral authority sites; and finally, where the question is genuinely community-shaped rather than clinical, a small amount of voice-of-customer colour without medical weight.

We do not cite Wikipedia, Reddit, Medium, Substack, YouTube, X threads, or vendor marketing pages as evidence. Vendor pages are sometimes linked for product context (price, formulation, regulatory class) but never as the source for an efficacy or safety claim.

When a claim is genuinely uncertain or the literature is split, we say so. The editorial voice rule is: hedge where the literature hedges; name the gaps where the human data is thin. Posts that pretend to have answers the field does not have are the editorial failure mode we treat as a critical error.

5. Affiliate and partner-supplier disclosure

Klarovel earns a commission on transactions completed through links to our vetted distributor network. The decision to feature a distributor is made on quality, third-party testing, supply consistency, and regulatory posture, not on commission rate. When we add a distributor to the network we document the criteria we evaluated them against and the public evidence (lab certificates of analysis, regulatory filings, customer-side complaint history) we relied on.

Editorial coverage of a peptide is not contingent on whether a distributor in our network supplies it. We write about peptides whose distributors we do not link to, and we will continue to do so where the topic warrants coverage. Conversely, we will not soften an unfavourable safety or evidence assessment of a peptide simply because a network distributor sells it.

Klarovel does not sell peptides directly, does not hold inventory, and does not handle physical fulfilment. The partner supplier ships the order under its own regulatory posture and customer-protection framework. This separation is not a marketing line; it is the legal and operational shape of the platform.

This disclosure satisfies the United States Federal Trade Commission's 16 CFR Part 255 endorsement guides, the European Union's Unfair Commercial Practices Directive (2005/29/EC), and the Norwegian Forbrukertilsynet's guidance on hidden marketing.

6. No medical advice

Nothing on Klarovel is medical advice, diagnosis, or treatment. Reading our content does not establish any clinician-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or modifying any peptide regimen, especially if you are pregnant, nursing, have a medical condition, or are taking prescription medication.

Specific scenarios where a clinical consult is not optional: active or historical cancer of any kind (most peptides with growth-promoting or angiogenic activity are contraindicated); cardiovascular disease (GH-axis peptides shift fluid balance and may aggravate left-ventricular load); type 1 or insulin- dependent type 2 diabetes alongside any GLP-1 class consideration (hypoglycaemia risk from concomitant insulin or sulfonylureas); pregnancy, lactation, or actively trying to conceive (most peptides are unstudied or contraindicated); and any active psychiatric care, particularly involving serotonergic agents (overlap with serotonergic peptides like Selank or Semax).

A Klarovel protocol is not a substitute for that consult. It is a structured document the reader can bring to a qualified clinician for clinical sign-off before any in-vivo use.

7. Research purposes only

Peptides supplied through the distributor network we link to are provided for research purposes only. Klarovel does not direct, supervise, or endorse any in vivo human use. Local laws on the possession, importation, and use of peptides vary widely by jurisdiction; readers are responsible for understanding and complying with the rules that apply where they live.

Specific jurisdictional notes that change the analysis: in the United States, BPC-157 and several other compounds are excluded from compounding pharmacies under FDA's 503A/503B bulks lists, which restricts but does not eliminate research supply; in the European Union, peptides without a marketing authorisation cannot be supplied for human medical use, though research-use supply varies by member state; in Australia, the TGA has issued a standing safety alert on imported unapproved peptides; in Norway, Statens legemiddelverk treats peptides without a marketing authorisation as unapproved medicinal products and customs may intercept personal-import shipments. None of these notes constitutes legal advice and all are subject to revision.

8. What we do not publish

We do not publish forum-derived dosing protocols dressed up as clinical guidance, "before and after" weight-loss photos, anecdotal protocols with no mechanism or evidence base, stack-of-the-month recommendations untethered to a goal profile, or content optimised for a search query that the available evidence cannot honestly support.

We also do not label individual peptides as "investigational" or "experimental" in public-facing copy, because the catalogue we carry is curated against research-consensus + clinician-support criteria upfront. A peptide either meets the catalogue criteria and is presented in full, or it is not in the catalogue. The internal evidence tiers (FDA-approved, strong clinical, moderate clinical, preclinical, experimental) drive engine scoring weights but are not exposed in the protocol output.

9. Update and freshness policy

Posts are scheduled for refresh on a 90-day cycle for top performers and a 180-day cycle by default. Refreshes can also be triggered out-of-cycle by: regulatory changes, new peer-reviewed studies, recall or safety notices, or significant pricing shifts in the distributor network.

Each post surfaces both its original publication date and its most recent review date so readers can judge freshness independently of our schedule. Posts that have aged past their refresh window without an intervening review are flagged internally and routed to the editorial queue; we do not silently leave stale clinical claims in place.

10. Corrections

We correct material errors quickly. If you spot one, write to editorial at klarovel dot com with the post URL and a citation to the corrected fact. Corrections that change a load-bearing claim are noted at the foot of the post; corrections that are purely cosmetic (a typo, a grammar fix) are made silently. The distinction is whether a reader would have acted differently based on the prior version of the claim.

11. Data handling

Users who create a Klarovel account submit a health questionnaire containing data that qualifies as a special category of personal data under GDPR Article 9. We treat that data accordingly: row-level security at the database layer so no user can read another user's questionnaire or protocol; no sharing with advertising networks; no use of the questionnaire data for model training. The full technical and legal treatment is documented in the privacy policy.

12. Contact

Editorial questions: editorial at klarovel dot com. Privacy: privacy policy. Terms: terms of use.